Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Yahoo! Finance
the company reported the Phase 2 TOIVA readout for Qtorin rapamycin in cutaneous venous malformations. The firm says 10 of 15 patients presented as “much improved” or “very much improved” over just 12 weeks. Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See Insiders' Hot Stocks on TipRanks Read More on PVLA: Disclaimer & Disclosure Report an Issue Palvella Therapeutics price target raised to $212 from $122 at Lucid Capital Palvella Therapeutics Reports Positive Phase 2 Study Results Palvella Therapeutics announces topline results from Phase 2 TOIVA trial Positive Buy Rating for Palvella Therapeutics Driven by Promising Developments in DSAP Treatment Palvella Therapeutics:
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics (NASDAQ:PVLA) was given a new $204.00 price target on by analysts at Canaccord Genuity Group Inc..MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $97.00 to $133.00. They now have a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..MarketBeat
- Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of AngiokeratomasGlobeNewswire
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 12/15/25 - Form 8-K
- 11/21/25 - Form 4
- 11/19/25 - Form 144
- PVLA's page on the SEC website